Patent Issued for Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof (USPTO 11897940).

A patent has been issued for broadly neutralizing anti-HIV-1 antibodies and their methods of use. HIV is a lentivirus that infects humans and can lead to acquired immunodeficiency syndrome (AIDS). The patent describes the development of antibodies that can neutralize multiple strains of HIV-1, which is the most clinically significant subtype. The invention includes specific antibodies and their variable regions, as well as methods for producing and using these antibodies. This patent was filed by inventors from Rockefeller University and published online on February 13, 2024. [Extracted from the article]

Copyright of AIDS Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)